Beauty Ambassade Journal · Longevity Science
Can Medicine Extend Human Life?
Medicine already prevents many premature deaths. That is different from proving that a pill slows biological aging or makes healthy people live longer.
The essential distinction
Disease prevention is real. A proven anti-aging drug is not.
Vaccination, blood-pressure control, evidence-based cholesterol treatment and effective care for diabetes can reduce the risk of illness and premature death in the right patient. These are major achievements of medicine, but they do not demonstrate that aging itself has been reversed.
As of this update, the U.S. Food and Drug Administration states that no medication has been proven to slow or reverse the aging process. Promising results in cells, mice or short human biomarker studies should therefore be described as research—not as established life extension.
What does “prolonging life” actually mean?
Lifespan
The number of years a person lives. Proving an effect on lifespan requires long follow-up and clinically meaningful endpoints, not simply a change in a laboratory marker.
Healthspan
The years lived with good function and without disabling disease. Preventing cardiovascular events, fractures, infections and cancer can protect healthspan even if a drug does not target aging itself.
Biomarkers
Measurements such as inflammation, metabolic markers or epigenetic clocks may help researchers test hypotheses. None is yet a universally accepted substitute for showing less disease, better function or longer survival.
The medicines most often discussed in longevity research
mTOR pathway
Rapamycin and rapalogs
Rapamycin extends lifespan in several animal models. A 2024 systematic review of human studies found some improvements in immune, cardiovascular and skin-related physiological measures, but no proof of longer human life.
These prescription drugs can also cause clinically important adverse effects and interactions. Their risk–benefit balance for healthy people remains unknown.
Promising, not proven for human longevityMetabolic pathway
Metformin
Metformin is a well-established treatment for type 2 diabetes. Observational studies have generated longevity hypotheses, but healthier-user effects and differences between patients can distort such comparisons.
A 2025 vertebrate meta-analysis found a consistent lifespan signal for rapamycin, but not for metformin. That animal evidence still cannot establish benefit in healthy humans.
Indicated for disease, unproven as anti-aging therapyCellular senescence
Senolytics
Senolytics are intended to remove selected senescent cells. Animal studies are compelling, while early human trials generally involve small samples or specific diseases rather than healthy adults followed for lifespan.
Senescent cells can also participate in wound repair and other normal processes, so indiscriminate removal is not automatically beneficial.
Early clinical researchSupplements and precursors
NAD+ products and resveratrol
NAD+ precursors can alter blood metabolites, and resveratrol affects aging-related pathways in laboratory models. Human trials have not established that either category extends lifespan.
“Natural” does not guarantee effective, pure or interaction-free. A supplement should not replace proven treatment or be added to a medication regimen without a safety review.
Insufficient evidence for life extensionThe evidence pathway
More preventive medication does not always mean more healthy years
The ASPREE lesson
Low-dose aspirin was once commonly viewed as broadly protective. ASPREE randomized 19,114 healthy older adults without a prior cardiovascular event to aspirin or placebo.
Aspirin did not prolong survival free of dementia or persistent physical disability. It did, however, increase clinically significant bleeding. This does not mean aspirin has no medical uses—it remains appropriate for some people with a clear indication—but it should not be self-prescribed as a general longevity strategy.
ASPREE randomized trial
Clinically significant bleeding
Share of participants experiencing major bleeding during the reported trial period.
Source: NIH/NIA summary of ASPREE. The population was healthy older adults, and the result should not be generalized to people taking aspirin for an established cardiovascular indication. Absolute difference: 1.1 percentage points.
How to assess a longevity claim
- Look at the species. Results in yeast, worms or mice are not results in people.
- Look at the endpoint. A biomarker is weaker evidence than better function, fewer diseases or longer survival.
- Look at the comparison. Randomized placebo-controlled trials reduce bias better than testimonials or observational comparisons.
- Look at the population. A benefit in a disease group may not apply to healthy people.
- Look at duration. Aging is slow; a brief study cannot prove decades of benefit or long-term safety.
- Look at harms. Interactions, infection, bleeding and metabolic effects can outweigh a speculative benefit.
- Look for replication. One small study rarely settles a medical question.
- Check the claim itself. “Supports a pathway” is not equivalent to “extends life.”
What longevity-focused medicine can responsibly do today
Reduce established risks
Good preventive care identifies risks that can be treated now: high blood pressure, abnormal lipids, diabetes, tobacco exposure, infection risk, osteoporosis and cancers for which screening is recommended. Treatment should be individualized by a qualified clinician.
Sleep, physical activity, nutrition, social connection and mental health remain central because no experimental compound cancels the effects of an unhealthy foundation.
Keep research in perspective
Geroscience is a serious and rapidly developing field. Rapalogs, metformin, senolytics and other approaches may eventually improve healthspan, but current enthusiasm is ahead of definitive human evidence.
The scientifically honest position is hopeful but cautious: use proven medicine for proven indications, participate in well-designed trials when appropriate, and avoid unsupervised “longevity stacks.”
Scientific sources
- U.S. Food and Drug Administration: Anti-aging medication health fraud
- Geroscience: A Translational Review (JAMA, 2025)
- Targeting ageing with rapamycin and its derivatives in humans: a systematic review (The Lancet Healthy Longevity, 2024)
- Rapamycin, Not Metformin, Mirrors Dietary Restriction-Driven Lifespan Extension in Vertebrates: A Meta-Analysis (Aging Cell, 2025)
- National Institute on Aging: ASPREE trial summary
- CALERIE trial analysis of calorie restriction and DNA-methylation measures (Nature Aging, 2023)
This article is for education only and is not medical advice. Do not start, stop or change aspirin, metformin, rapamycin, supplements or any other treatment without discussing your health history, medications and risks with a licensed clinician.
Care for the skin you live in today.
Our spa services support visible skin health and wellbeing; they are not medical longevity treatments and do not claim to alter lifespan.